NYSE · BRKR
Healthcare · Medical - Devices
$62.00
Down-$4.93 (-7.95%)
Updated Oct 31, 2026, 1:03 AM
SID Score
6.0/10
Composite research score
Smart Money
58/100
Neutral
Price performance · BRKR
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 29, 2026
BRKR closed at $62.00 after 20 trading sessions, down 1.96% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2026 | $61.18 | $62.54 | $61.00 | $62.00 | 1.5M |
| Oct 28, 2026 | $60.66 | $63.39 | $60.55 | $62.00 | 2.99M |
| Oct 27, 2026 | $58.43 | $61.00 | $57.745 | $60.74 | 2.38M |
| Oct 26, 2026 | $57.79 | $58.30 | $57.275 | $58.23 | 2.33M |
| Oct 23, 2026 | $56.93 | $57.7785 | $55.32 | $57.59 | 1.22M |
| Oct 22, 2026 | $59.11 | $60.665 | $55.52 | $57.31 | 2.37M |
| Oct 21, 2026 | $55.42 | $59.49 | $55.42 | $59.105 | 3.56M |
| Oct 20, 2026 | $55.52 | $56.94 | $54.85 | $55.93 | 1.57M |
| Oct 19, 2026 | $54.89 | $56.20 | $54.68 | $55.37 | 1.91M |
| Oct 16, 2026 | $56.45 | $57.18 | $54.265 | $54.80 | 1.67M |
| Oct 15, 2026 | $54.97 | $57.01 | $54.44 | $56.54 | 2.11M |
| Oct 14, 2026 | $55.39 | $58.08 | $54.57 | $55.60 | 2.34M |
| Oct 13, 2026 | $55.64 | $56.665 | $54.83 | $56.19 | 2.17M |
| Oct 12, 2026 | $58.75 | $58.75 | $55.89 | $56.25 | 1.86M |
| Oct 9, 2026 | $57.92 | $59.56 | $57.555 | $58.84 | 1.47M |
| Oct 8, 2026 | $59.23 | $59.23 | $56.29 | $57.92 | 2.56M |
| Oct 7, 2026 | $60.85 | $61.375 | $57.33 | $59.72 | 2.91M |
| Oct 6, 2026 | $64.67 | $66.415 | $59.295 | $60.50 | 2.9M |
| Oct 5, 2026 | $63.12 | $64.48 | $62.65 | $63.86 | 2.02M |
| Oct 2, 2026 | $62.25 | $64.36 | $62.25 | $63.24 | 2.23M |
The latest Smart Investors Daily articles mentioning BRKR.
Company
Market Activity
Research & News
BRKR research
Company profile and research snapshot.
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 14, 2026 | JP Morgan | Neutral | — |
| Oct 13, 2026 | TD Cowen | Hold | — |
| Oct 7, 2026 | Barclays | Overweight | — |
| Oct 1, 2026 | Guggenheim | Buy | — |
| Sep 29, 2026 | Leerink Partners | Outperform | — |
No generated briefing is available yet.
Yahoo · Oct 20, 2026
BILLERICA, Mass., October 20, 2026--Bruker Corporation (Nasdaq: BRKR) today announced it will report third quarter 2026 financial results before market opening on Wednesday, November 4, 2026. The Company will host a conference call and webcast at 8:30 a.m. Eastern Daylight Time to discuss the results and current business trends.
Benzinga · Oct 14, 2026
JP Morgan analyst Casey Woodring downgrades Bruker (NASDAQ:BRKR) from Overweight to Neutral and announces $60 price target.
Benzinga · Oct 13, 2026
TD Cowen analyst Kyle Boucher maintains Bruker (NASDAQ:BRKR) with a Hold and raises the price target from $60 to $62.
Yahoo · Oct 12, 2026
Bruker has been on fire lately. In the past six months alone, the company’s stock price has rocketed 50.7%, reaching $58.84 per share. This run-up might have investors contemplating their next move.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BRKR.
